Kasper Lamberth

Malov, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.

Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.

Journal: Pharmaceutical research
Published: February 23, 2026

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Journal: Pharmaceutical research
Published: August 30, 2024

Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog.

Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog.

Journal: Journal of medicinal chemistry
Published: July 16, 2024

Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.

Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.

Journal: The AAPS journal
Published: March 20, 2023

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.

Journal: mAbs
Published: December 20, 2021

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.

Journal: Blood
Published: December 10, 2020

Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.

Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.

Journal: Immunology
Published: July 17, 2020

In silico and in vitro immunogenicity assessment of B-domain-modified recombinant factor VIII molecules.

In silico and in vitro immunogenicity assessment of B-domain-modified recombinant factor VIII molecules.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: May 26, 2018

The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.

The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.

Journal: PloS one
Published: January 31, 2018

Engineering of a membrane-triggered activity switch in coagulation factor VIIa.

Engineering of a membrane-triggered activity switch in coagulation factor VIIa.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 08, 2017

Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.

Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.

Journal: PloS one
Published: November 07, 2016

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.

Journal: Science translational medicine
Published: January 04, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026